MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. develops innovative treatments for cancer and immune-mediated diseases using allogeneic, ex-vivo expanded invariant natural killer T ("iNKT") cells. iNKT cells are a distinct T cell population that combines the durable memory responses of adaptive T cells with the rapid, MHC-independent cytolytic capabilities of natural killer ("NK") cells. This dual functionality allows for direct tumor killing, orchestration of the tumor microenvironment, elimination of immunosuppressive myeloid populations, and restoration of exhausted T-cell function, while naturally suppressing graft-versus-host disease ("GvHD"). This makes iNKT cells an optimal platform for allogeneic therapy due to their natural homing capabilities, tumor clearance potential, and efficacy against infected cells. The company advances both native and engineered iNKT cell therapies through a pipeline of wholly owned or exclusively licensed assets. MiNK Therapeutics has also developed a proprietary personalized neoantigen library to facilitate personalized T Cell Receptor ("TCR") development. This library identifies patient-specific tumor neoantigens to create tailored TCR-based therapies, aiming to enhance precision, efficacy, and therapeutic outcomes for patients with various cancers and immune-mediated diseases. The company's goal is to discover, develop, and commercialize novel allogeneic, off-the-shelf, iNKT cell therapies for cancer and other immune-mediated diseases with high unmet needs. MiNK Therapeutics employs iNKT cells in their native form through its lead program, agenT-797, in diseases where iNKT cells have shown activity and accelerated approval pathways exist. These indications include critical pulmonary immune failure (including severe hypoxemic respiratory failure / pneumonia), GvHD, solid tumor cancers, and other severe immune-related diseases.